Schmitz brings experience from previous jobs at AstraZeneca, Orthomol, Novartis and ProStakan. In 2012 he started his own business as a management consultant. Recently, he worked in Otsuka’s special division for two years. In Düsseldorf he succeeds Christian Vierkant, who left the company after twelve years.
“I am really looking forward to the exciting challenge. This includes expanding the RX business primarily of Gelderma Germany and Austria and strengthening the respective development of categories. Above all, the product will be launched in the area of acne and psoriasis, a major focus for us, ”said Schmitz.
Other brands that his team oversees are Actinica, Luxaram, Metavix, Selgamis and Solentra. The RX division contributes about a quarter to the most recent turnover of 106 million euros, about half of the OTC division, which is managed by Stephanie Schulz. The rest of the brand is in the aesthetics sector along with Ezel and Restlen.
Galderma was founded in 1981 as a joint venture between Nestlé and L’Oreal. In 2014 Nestle took over 50 percent of its long-term partner. In late 2019, Galderma was sold to a consortium led by Swedish investor EQT and Abu Dhabi Investment Authority (ADIA) for around 9 billion euros. Other investors include Centro Holding of the Strungman family and the Canadian Pension Fund Manager Public Sector Pension Investment Board (PSP). Marion Bock is the Managing Director for Germany.
Stay up to date and subscribe to the APOTHEKE ADHOC newsletter.
